Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A First Human Dose Study to Assess the Safety, Tolerability, Pharmacokinetics and Target Engagement of Single Doses of NNC6022-0001 in Healthy Adults.

Next Previous
Search
Trial Profile

A First Human Dose Study to Assess the Safety, Tolerability, Pharmacokinetics and Target Engagement of Single Doses of NNC6022-0001 in Healthy Adults.

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 21 Apr 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs NNC 6022 0001 (Primary)
  • Indications Cardiovascular disorders; Metabolic disorders
  • Focus Adverse reactions; First in man
  • Sponsors Novo Nordisk

Most Recent Events

  • 16 Apr 2025 Status changed from active, no longer recruiting to completed.
  • 04 Mar 2025 Planned End Date changed from 17 Oct 2024 to 11 Mar 2025.
  • 04 Mar 2025 Planned primary completion date changed from 17 Oct 2024 to 11 Mar 2025.

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top